About 20–50% of hepatitis C and cancer patients who have undergone interferon-α (IFNα) therapy are estimated to develop clinically significant depression [209], associated with high serum levels of sIL-2r, TNFα, and IL-6 [210]. This evidence concerns the gene IL6 and major depressive disorder.